AzTrials
AzTrials

Benign Prostatic HyperplasiaNCT05543200

BPH Global Registry

An observational study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, run by Société Internationale d'Urologie at 30 sites in 21 countries.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. Read more about this study

Who is it for?
Ages 18 years and older, men only
How many people
7,500 participants
Where
30 sitesin 21 countries
Study dates
13 Mar 2023to Dec 2028
How long will I take part?
3 Years
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Men only
  • No healthy volunteers
  • Adult, Older adult

Study population: All patients >18 years with symptomatic BPH with LUTS who are planned for medical or surgical intervention are eligible for this study.

Who may be able to join

  • Primary diagnosis of BPH with LUTS with prescribed medical treatment or surgical intervention

Who cannot join

  • Non-symptomatic BPH
  • No treatment prescribed for BPH

Trial locations and contacts

30 sites in 21 countries. Contact the study team or a site near you to ask about taking part.

30 sites in 21 countries

Canada3 sites, 3 recruiting
  • McGill University Health Centre

    Montreal, Quebec

    Mélanie Aubé-Peterkin, MD, melanieaubep@gmail.com

    Mélanie Aubé-Peterkin, MD

    Recruiting
  • University of Montreal Hospital Center

    Montreal

    Abbas Guennoun, abbas.guennoun.chum@ssss.gouv.qc.ca

    Naeem Bhojani, MD

    Not yet recruiting
  • Toronto Western Hospital, University Health Network

    Toronto, Ontario

    Iris Chan, Iris.Chan2@uhn.ca

    Dean Elterman, MD, MSc, FRCSC

    Recruiting

Other trials in Canada

Kenya3 sites, 3 recruiting
  • Gracepark Medical Centre

    Meru

    Elias Nyaga, MD, drnyagaem@gmail.com

    Elias Nyaga, MD

    Not yet recruiting
  • Pandya Memorial Hospital

    Mombasa

    Sundeep Chavda, MD, schavda@hotmail.com

    Sundeep Chavda, MD

    Not yet recruiting
  • Kenyatta National Hospital

    Nairobi

    Carnjini Yogeswaran, MD, carnjini@gmail.com

    Carnjini Yogeswaran, MD

    Not yet recruiting

Other trials in Kenya

Chile2 sites, 2 recruiting
  • Hospital Dr. Juan Morey La Unión

    La Unión

    Fernando Segura, MD, fernando.seguradiaz@gmail.com

    Fernando Segura, MD

    Recruiting
  • Hospital del Trabajador

    Santiago

    Reynaldo Gomez, MD, gomez.reynaldo@gmail.com

    Reynaldo Gomez, MD

    Recruiting

Other trials in Chile

Italy2 sites, 2 recruiting
  • Azienda Ospedaliero-Universitaria Careggi

    Florence

    Edoardo Dibilio, MD, edoardo.dibilio@unifi.it

    Mauro Gacci, MD

    Recruiting
  • Sapienza University of Rome, Division of Urology, Ospedale Sant'Andrea

    Rome

    Antonio Nacchia, MD, antonionacchia7@gmail.com

    Cosimo De Nunzio, MD, PhD

    Recruiting

Other trials in Italy

Nigeria2 sites, 2 recruiting
  • Benue State University Teaching Hospital, Department of Surgery

    Makurdi

    Christian Agbo, MD, agbo535@gmail.com

    Christian Agbo, MD

    Recruiting
  • Ahmadu Bello University Teaching Hospital

    Zaria

    Nasir Oyelowo, MD, nasiroyelowo@gmail.com

    Nasir Oyelowo, MD

    Recruiting

Other trials in Nigeria

Pakistan2 sites, 2 recruiting
  • Institute of Kidney Diseases Peshawar

    Peshawar

    Abdul Haseeb, MD, ahaseeb.dr@gmail.com

    Abdul Haseeb, MD

    Recruiting
  • Lady Reading Hospital

    Peshawar

    Muhammad Asif, MD, drasif_15@yahoo.com

    Muhammad Asif, MD

    Recruiting

Other trials in Pakistan

United Kingdom2 sites, 2 recruiting
  • Imperial College Healthcare NHS Trust

    London

    Ranan Dasgupta, MD

    Ranan Dasgupta, MD

    Not yet recruiting
  • Southend University Hospital

    Southend-on-Sea

    Daben Dawam, MD, d.dawam@nhs.net

    Daben Dawam, MD

    Recruiting

Other trials in United Kingdom

United States1 site, 1 recruiting
  • Keck Medicine of USC

    Los Angeles, California, 90089

    Mihir Desai, MD

    Mihir Desai, MD

    Recruiting

Other trials in United States

China1 site, 1 recruiting
  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou

    Ben Liu, MD, drliuben@sina.com

    Ben Liu, MD

    Recruiting

Other trials in China

Cyprus1 site, 1 recruiting
  • University of Cyprus

    Nicosia

    Stavros Gravas, MD, Phd, sgravas2002@yahoo.com

    Satvros Gravas, MD

    Not yet recruiting

Other trials in Cyprus

Hong Kong1 site, 1 recruiting
  • The Chinese University of Hong Kong

    Hong Kong

    Alex Qinyang Liu, MD, alexliu@surgery.cuhk.edu.hk

    Alex Qinyang Liu, MD

    Not yet recruiting

Other trials in Hong Kong

India1 site, 1 recruiting
  • Dr Baba Saheb Ambedkar Medical College and Hospital

    Delhi

    Mohammad Shazib Faridi, MD, drshazibfaridi@gmail.com

    Mohammad Shazib Faridi, MD

    Recruiting

Other trials in India

Iran1 site, 1 recruiting
  • Shariati Hospital

    Tehran

    Seyed Reza Yahyazadeh, MD, r.yahyazadeh@gmail.com

    Seyed Reza Yahyazadeh, MD

    Recruiting

Other trials in Iran

Iraq1 site, 1 recruiting
  • University of Basrah

    Basra

    Murtadha Almusafer, MD, murtadha.majeed@uobasrah.edu.iq

    Murtadha Almusafer, MD

    Recruiting

Other trials in Iraq

Lebanon1 site, 1 recruiting
  • American University of Beirut

    Beirut

    Yara Ghandour, MD, yg10@aub.edu.lb

    Albert El Hajj, MD

    Recruiting

Other trials in Lebanon

Malaysia1 site, 1 recruiting
  • Universiti Malaya

    Kuala Lumpur

    Shanggar Kuppusamy, MD, PhD, shanggar@ummc.edu.my

    Shanggar Kuppusamy, MD, PhD

    Recruiting

Other trials in Malaysia

Mali1 site, 1 recruiting
  • Kati University Hospital

    Kati

    Idrissa Sissoko, MD, idrississoko@gmail.com

    Idrissa Sissoko, MD

    Recruiting

Other trials in Mali

Mexico1 site, 1 recruiting
  • Centro Medico Nacional Siglo XXI

    Mexico City

    Laura Coretta Mejia Rios, MD, dralau.coretta@gmail.com

    Laura Coretta Mejia Rios, MD

    Recruiting

Other trials in Mexico

Qatar1 site, 1 recruiting
  • Hamad Medical Corporation Qatar

    Doha

    Kamran Bhatti, MD, kamibhatti92@gmail.com

    Kamran Bhatti, MD

    Recruiting

Other trials in Qatar

South Korea1 site, 1 recruiting
  • Seoul National University Bundang Hospital

    Seongnam

    Sang Hun Song, MD, shsong@snubh.org

    Sung Kyu Hong, MD

    Not yet recruiting

Other trials in South Korea

Turkey (Türkiye)1 site, 1 recruiting
  • Istanbul Medipol University

    Istanbul

    Bulent Erkurt, MD, berkurt@medipol.edu.tr

    Bulent Erkurt, MD

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: A Global Registry of Treatments and Outcomes for Benign Prostatic Hyperplasia

Benign prostatic hyperplasia (BPH) is one of the most common performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been standardized. While data are available for the initial pivotal studies, post-market release data are lacking. Under the umbrella of uCARE, we have started a prospective, ongoing international registry for recording demographics and outcomes for patients undergoing surgical treatments for BPH.

Read the detailed description

Due to a growing and aging population, cases of benign prostatic hyperplasia (BPH) have been on a steady rise. Studies show that by age 80, 90% of men experience BPH. (Garraway, Lee, Collins, 1991) Thus, treatment of BPH is one of the most performed surgical procedures in urology. Over the past few decades there have been an increasing development of newer surgical treatment options. Additionally, the outcome parameters for BPH treatments have been somewhat standardized. The purpose of this study is to create an ongoing prospective registry to record demographic data and clinical outcomes after medical therapy or different surgical interventions for BPH. The specific aims of the registry are to analyze demographic patterns and baseline characteristics of men undergoing surgical and medical treatments for BPH, to assess global practice patterns for various surgical and medical treatments of BPH, and to assess key outcomes for uni- and multi-modal treatments of BPH.

The ongoing global registry will provide important baseline data, functional outcomes, and complications following medical and/or surgical intervention for men with symptomatic BPH. The intention of the registry is to provide real world usage data that may be used for future investigations. It will allow providers to identify areas of interest, areas of unusually low usage or areas of unusual preference on a global scale. It will also shed light on global preferences for unimodal or multimodal approaches to treatments.

The registry has been developed using novel database technology, providing an easy-to-use user interface, which enables future creation of patient portals and Electronic Medical Record (EMR) integration.

As this is not an experimental setting, there will be no interventions made on behalf of the registry.

This is a prospective longitudinal ongoing registry. The study will include medical records of all men ≥18 years old who have a primary diagnosis of BPH with Lower Urinary Tract Symptoms (LUTS) that are prescribed BPH medications, or a surgical intervention. Data extraction includes baseline data, peri-operative data, and follow-up data. Baseline data includes validated patient reported outcome tools, including International Prostate Symptom Score (IPSS), Sexual Health Inventory for Men (SHIM), Male Sexual Health Questionnaire - Ejaculatory Dysfunction (MSHQ-EjD), as well as Quality of Life (QoL), maximum flow rate (Qmax), Post-void residual (PVR), Prostate Specific Antigen (PSA), and Testosterone. Complications such as Bleeding, Urinary Tract Infection (UTI), Incontinence, Stricture, Retrograde ejaculation, and Erectile Dysfunction (ED) are also tracked from Baseline through Follow-up.

The registry will run for 3 years with no end point for follow-up. For three years, various research studies will be formulated, and the results will be published. The possibility of extending the study for continued follow-up will be evaluated.

A built-in quality control using data validation during the input process decreases the chance that invalid data will be entered or that datapoints will be omitted. Periodic audits will be performed to verify accuracy of source data by our audit committee based on our audit committee guidelines.

Records and cases of all men with a primary diagnosis of BPH with LUTS that are prescribed BPH medications, or a surgical intervention will be identified and included in the registry. All data is hashed (i.e., protected from decryption) except for a medical record number (MRN), which will be used to add follow-up data to the patient's record. This number is encrypted and linked to the hashed and randomly generated institution code. For security purposes, biographical information is not saved on the registry.

The registry provides secure access to registered users using a web browser. Registrations are site-specific, which means that users can only access the data that is specific to their own site. The registry application and databases are hosted on secure, encrypted servers behind a firewall. They can only be accessed by registered users via a specific port.

Keywords
BPH, Registry, LUTS
Medical subject headings
Prostatic Hyperplasia, Lower Urinary Tract Symptoms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05543200
Study groupRoleWhat they receive
All ParticipantsAll men who have a primary diagnosis of BPH with LUTS that are prescribed BPH medications or a surgical intervention.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. International Prostate Symptom Score (IPSS)

    Comparison of mean IPSS score change between baseline and at each follow-up during the course of the study. The scale goes from 0 (Mild) to 35 (Severe).

    Measured: 36 months

  2. Quality of Life (QoL)

    Comparison of mean QoL score change between baseline and at each follow-up during the course of the study. The scale is a single question which ranges from 0 to 6, with higher numbers indicating a worse quality of life.

    Measured: 36 months

  3. Post-Void Residual (PVR)

    Comparison of mean PVR change between baseline and at each follow-up during the course of the study.

    Measured: 36 months

  4. Complications (including incontinence)

    Type and Clavien grade incidences across all surgical interventions.

    Measured: 36 months

Secondary outcomes (4)
  1. Prostate Volume (cc)

    Comparison of mean Prostate Volume change between baseline and at each follow-up during the course of the study.

    Measured: 36 months

  2. Qmax

    Comparison of mean Qmax change between baseline and at each follow-up during the course of the study.

    Measured: 36 months

  3. Male Sexual Health Questionnaire Ejaculatory Dysfunction (MSHQ-EjD)

    Comparison of mean MSHQ-EjD score change between baseline and at each follow-up during the course of the study. The scale ranges from 1 to 15 with a higher score indicating better sexual functioning.

    Measured: 36 months

  4. Sexual Health Inventory for Men (SHIM)

    Comparison of mean SHIM score change between baseline and at each follow-up during the course of the study.

    Measured: 36 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Sep 2022
  2. Study start13 Mar 2023
  3. Primary completionDec 2027 (estimated)
  4. Study completionDec 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
7,500 participants (estimated)
Target duration
3 Years
IDs, dates and publications
ClinicalTrials.gov ID
NCT05543200
Sponsor's protocol ID
uCARE-2022-001
Status last verified
Aug 2026
First submitted
13 Sep 2022
Last updated
13 Aug 2026
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms, run by Société Internationale d'Urologie at 30 sites in 21 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 13 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 30 sites in Canada, Kenya, Chile, Italy, Nigeria and 16 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Mihir Desai, MD (+1 (323) 865 3700, mihir.desai@med.usc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

International Prostate Symptom Score (IPSS) (time frame: 36 months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Aug 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in